FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912056898> ?p ?o ?g. }

• W2912056898 endingPage "2078" @default.
• W2912056898 startingPage "2078" @default.
• W2912056898 abstract "Abstract Background : While dCBT is associated with high rates of sustained donor engraftment, delayed neutrophil recovery in adults is frequent and can contribute to extended hospitalization and early transplant-related mortality. Methods : We investigated engraftment after myeloablative dCBT supplemented with CD34+ selected haploidentical PBSC (haploCD34+) in patients (pts) with high risk hematologic malignancies or aplastic anemia in a phase II clinical trial. The aim was to abrogate neutropenia (ANC >/= 500 within 14 days) with a haplo myeloid bridge prior to CB engraftment. Pts did not receive ATG due to the increased mortality risk reported in adult CBT. Double unit CB grafts allowed comparison to dCBT controls without haploidentical graft supplementation. Results : 78 adult pts [median age 48.5 years (range 21-68), median weight 82 kgs (range 48-138), 44 (56%) CMV+, 3 with prior allografts] underwent haplo-dCBT between 9/2012-12/2017. Diagnoses included 54 (69%) acute leukemias, 10 (13%) MDS/ MPN (all ≤ 10% blasts at work-up), 10 (17%) NHL/ HD and 1 aplastic anemia. Conditioning was myeloablative (1 Cy 120/ Flu 75/ TBI 1375, 77 intermediate intensity Cy 50/ Flu 150/ Thio 5-10/ TBI 400) with CSA/ MMF. CB units had a median infused TNC of 2.3 (range 1-5.7) x 107/kg/unit & median infused viable CD34+ cell dose of 1.1 (range 0.1-3.1) x 105/kg/unit with a median 5/8 (range 2-7) unit-recipient HLA-allele match. Haplo CD34+ grafts [procured from children (46%), siblings (31%), parents (13%) or extended family (10%)] had a median infused CD34+ dose of 5.2 x 106/kg (range 1.1-16.8) and a median infused CD3+ dose of 1.6 x 103/kg (range 0.3-13.7). Sixty-one (78%) haplos were 4/8 and 17 (22%) were 5-7/8 HLA-matched to the pt. In 77 evaluable pts (1 pt died on day 14), 4 engraftment patterns were observed (Table 1). All but 2 pts had sustained CB engraftment with either an optimal haplo-bridge (Gp. 1, 34/77, 44%), a transient bridge with a second nadir preceding CB engraftment (Gp. 2, 20/77, 26%), or no bridge (Gp. 3, 21/77, 27%). The 2 remaining pts had CB/ haplo graft failure (Gp. 4, 2/77, 3%); both were successfully re-transplanted with single CB units. While there was no difference in the day 100 TRM in the 34 optimal bridge pts vs pts with transient or no bridge [9% (95%CI 2-21) vs 15% (95%CI 6-27), p = 0.388], optimal bridge pts had faster platelet recovery [19 (range 14-41) vs 44.5 days (range 14-67)] and earlier hospital discharge [28.5 (range 20-60) vs 36 days (range 28-98)]. Similar to dCBT alone, chimerism analysis revealed sustained engraftment in haplo-dCBT is mediated by a winning CB unit. This was heralded by winning unit-derived T-cells seen as early as day +28. Although universal, the speed of haplo rejection varied, and a high haplo chimerism percentage early post-transplant did not guarantee successful bridging. Analysis of factors potentially predicting an optimal bridge is shown in Table 2. The median winning CB unit-haplo 8-allele HLA-match was 3/8 (range 1-7/8). In univariate analysis, higher haplo CD34+ dose/kg, > 4/8 haplo-recipient HLA-match and ≥ 3/8 winning unit-haplo HLA-match were associated with a higher likelihood of bridging. Haplo CD34+ dose and winning unit-haplo HLA-match remained significant in multivariate analysis. Conclusions: While haplo-dCBT can be associated with enhanced neutrophil recovery, this platform does not guarantee a successful myeloid bridge due to early haplo rejection by the winning CB unit. This universal haplo rejection highlights the importance of the CB graft dose and quality with this ATG-free strategy as the CB will mediate sustained engraftment. Our findings have significance for strategies that combine unmanipulated CB with any third-party or ex vivo expanded T-cell depleted product given higher product CD34+ cell dose and better HLA-match to the unmanipulated CB unit could improve the likelihood of successful myeloid bridging. The data also support alternative approaches to improve myeloid recovery after CBT such as optimized unit selection and vivo expansion. Disclosures O'Reilly: Atara Biotherapeutics: Consultancy, Patents & Royalties, Research Funding. Perales:Takeda: Other: Personal fees; Novartis: Other: Personal fees; Incyte: Membership on an entity's Board of Directors or advisory committees, Other: Personal fees and Clinical trial support; Merck: Other: Personal fees; Abbvie: Other: Personal fees. Sauter:Juno Therapeutics: Consultancy, Research Funding; Sanofi-Genzyme: Consultancy, Research Funding; Spectrum Pharmaceuticals: Consultancy; Novartis: Consultancy; Precision Biosciences: Consultancy; Kite: Consultancy. Shah:Janssen: Research Funding; Amgen: Research Funding." @default.
• W2912056898 created "2019-02-21" @default.
• W2912056898 creator A5000852934 @default.
• W2912056898 creator A5002993817 @default.
• W2912056898 creator A5003197311 @default.
• W2912056898 creator A5003503263 @default.
• W2912056898 creator A5003831049 @default.
• W2912056898 creator A5016160764 @default.
• W2912056898 creator A5021595775 @default.
• W2912056898 creator A5031248362 @default.
• W2912056898 creator A5031349996 @default.
• W2912056898 creator A5034628611 @default.
• W2912056898 creator A5035362303 @default.
• W2912056898 creator A5036520753 @default.
• W2912056898 creator A5043510888 @default.
• W2912056898 creator A5043966208 @default.
• W2912056898 creator A5044552886 @default.
• W2912056898 creator A5045167741 @default.
• W2912056898 creator A5047384277 @default.
• W2912056898 creator A5056539557 @default.
• W2912056898 creator A5058476408 @default.
• W2912056898 creator A5058746837 @default.
• W2912056898 creator A5064076262 @default.
• W2912056898 creator A5066163702 @default.
• W2912056898 creator A5069648775 @default.
• W2912056898 creator A5070096873 @default.
• W2912056898 creator A5070487002 @default.
• W2912056898 creator A5082333371 @default.
• W2912056898 creator A5085550690 @default.
• W2912056898 creator A5085595407 @default.
• W2912056898 date "2018-11-29" @default.
• W2912056898 modified "2023-10-17" @default.
• W2912056898 title "Double-Unit Cord Blood (CB) Transplantation with Haplo-Identical CD34+ Cells (haplo-dCBT) May Speed Neutrophil Recovery Although Successful Bridging Is Contingent on Close Haplo-Winning CB Unit HLA-Match" @default.
• W2912056898 doi "https://doi.org/10.1182/blood-2018-99-116276" @default.
• W2912056898 hasPublicationYear "2018" @default.
• W2912056898 type Work @default.
• W2912056898 sameAs 2912056898 @default.
• W2912056898 citedByCount "0" @default.
• W2912056898 crossrefType "journal-article" @default.
• W2912056898 hasAuthorship W2912056898A5000852934 @default.
• W2912056898 hasAuthorship W2912056898A5002993817 @default.
• W2912056898 hasAuthorship W2912056898A5003197311 @default.
• W2912056898 hasAuthorship W2912056898A5003503263 @default.
• W2912056898 hasAuthorship W2912056898A5003831049 @default.
• W2912056898 hasAuthorship W2912056898A5016160764 @default.
• W2912056898 hasAuthorship W2912056898A5021595775 @default.
• W2912056898 hasAuthorship W2912056898A5031248362 @default.
• W2912056898 hasAuthorship W2912056898A5031349996 @default.
• W2912056898 hasAuthorship W2912056898A5034628611 @default.
• W2912056898 hasAuthorship W2912056898A5035362303 @default.
• W2912056898 hasAuthorship W2912056898A5036520753 @default.
• W2912056898 hasAuthorship W2912056898A5043510888 @default.
• W2912056898 hasAuthorship W2912056898A5043966208 @default.
• W2912056898 hasAuthorship W2912056898A5044552886 @default.
• W2912056898 hasAuthorship W2912056898A5045167741 @default.
• W2912056898 hasAuthorship W2912056898A5047384277 @default.
• W2912056898 hasAuthorship W2912056898A5056539557 @default.
• W2912056898 hasAuthorship W2912056898A5058476408 @default.
• W2912056898 hasAuthorship W2912056898A5058746837 @default.
• W2912056898 hasAuthorship W2912056898A5064076262 @default.
• W2912056898 hasAuthorship W2912056898A5066163702 @default.
• W2912056898 hasAuthorship W2912056898A5069648775 @default.
• W2912056898 hasAuthorship W2912056898A5070096873 @default.
• W2912056898 hasAuthorship W2912056898A5070487002 @default.
• W2912056898 hasAuthorship W2912056898A5082333371 @default.
• W2912056898 hasAuthorship W2912056898A5085550690 @default.
• W2912056898 hasAuthorship W2912056898A5085595407 @default.
• W2912056898 hasBestOaLocation W29120568981 @default.
• W2912056898 hasConcept C10205521 @default.
• W2912056898 hasConcept C126322002 @default.
• W2912056898 hasConcept C141071460 @default.
• W2912056898 hasConcept C203014093 @default.
• W2912056898 hasConcept C2776694085 @default.
• W2912056898 hasConcept C2777063308 @default.
• W2912056898 hasConcept C2779282312 @default.
• W2912056898 hasConcept C2780007613 @default.
• W2912056898 hasConcept C2781440808 @default.
• W2912056898 hasConcept C28328180 @default.
• W2912056898 hasConcept C2911091166 @default.
• W2912056898 hasConcept C54355233 @default.
• W2912056898 hasConcept C71924100 @default.
• W2912056898 hasConcept C74133956 @default.
• W2912056898 hasConcept C86803240 @default.
• W2912056898 hasConcept C90924648 @default.
• W2912056898 hasConceptScore W2912056898C10205521 @default.
• W2912056898 hasConceptScore W2912056898C126322002 @default.
• W2912056898 hasConceptScore W2912056898C141071460 @default.
• W2912056898 hasConceptScore W2912056898C203014093 @default.
• W2912056898 hasConceptScore W2912056898C2776694085 @default.
• W2912056898 hasConceptScore W2912056898C2777063308 @default.
• W2912056898 hasConceptScore W2912056898C2779282312 @default.
• W2912056898 hasConceptScore W2912056898C2780007613 @default.
• W2912056898 hasConceptScore W2912056898C2781440808 @default.
• W2912056898 hasConceptScore W2912056898C28328180 @default.
• W2912056898 hasConceptScore W2912056898C2911091166 @default.
• W2912056898 hasConceptScore W2912056898C54355233 @default.
• W2912056898 hasConceptScore W2912056898C71924100 @default.
• W2912056898 hasConceptScore W2912056898C74133956 @default.

• next